COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Early PN trial
Scientific title
The effects of early parenteral nutrition compared to standard care on 60 day landmark mortality in the critically ill patient: A level I randomised
controlled trial.
Secondary ID [1] 280750 0
Universal Trial Number (UTN)
Trial acronym
Early PN trial®
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Critical Illness (ICU pts) 853 0
Condition category
Condition code
Diet and Nutrition 920 920 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Study type
Description of intervention(s) / exposure
Patients will be rdx to receive early parenteral nutrition or standard care. Early PN will be initiated within 24 h of ICU admission at a rate to achieve approx 25-30kcals/kg per day. Early PN will be maintained until enteral nutrition (EN) is initiated. In this effectiveness trial, the duration of early PN will be PRN. The duration of standard care will be determined at the discretion of the attending physician (PRN), as long as the patient remains in the ICU.
Intervention code [1] 742 0
Treatment: Other
Comparator / control treatment
Standard (active) care
Control group

Primary outcome [1] 1205 0
60 day all cause landmark mortality
Timepoint [1] 1205 0
Day 60
Secondary outcome [1] 2193 0
ICU and hospital length of stay
Timepoint [1] 2193 0
Measured at ICU and hospital discharge
Secondary outcome [2] 2194 0
Timepoint [2] 2194 0
Measured at day 60
Secondary outcome [3] 2195 0
Degree and days of organ dysfunction
Timepoint [3] 2195 0
Measured during ICU stay
Secondary outcome [4] 2196 0
Days of mechanical ventilation
Timepoint [4] 2196 0
Measured during ICU stay
Secondary outcome [5] 2197 0
Days of renal replacement therapy
Timepoint [5] 2197 0
Measured during ICU stay
Secondary outcome [6] 2198 0
Days of inotrope requirement
Timepoint [6] 2198 0
Measured during ICU stay
Secondary outcome [7] 2199 0
Daily blood glucose levels
Timepoint [7] 2199 0
Measured during ICU stay
Secondary outcome [8] 2200 0
Daily insulin dose
Timepoint [8] 2200 0
Measured during ICU stay
Secondary outcome [9] 2201 0
Duration and severity of pressure ulcers
Timepoint [9] 2201 0
Measured during ICU stay
Secondary outcome [10] 2202 0
Antibiotic usage
Timepoint [10] 2202 0
Measured during ICU stay
Secondary outcome [11] 2203 0
Measures of nutritional status
Timepoint [11] 2203 0
Measured during ICU stay

Key inclusion criteria
Patients will be screened for eligibility as soon as practical after admission to the study ICU. Patients will be considered eligible for the trial if the following criteria are addressed at the time of screening:Inclusion criteria: The patient is not currently receiving oral, enteral or parenteral nutritional support; The treating physician does not expect to begin oral, enteral or parenteral nutritional support within 24 hours.
Minimum age
Not stated
Maximum age
Not stated
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
The treating physician expects to discharge the patient from the ICU within 24 hours; The patient's ICU length of stay at time of screening is greater than 24 hours; Parenteral nutrition cannot be started within 24 hours of ICU admission; There is an absolute contraindication for enteral nutrition and the patient would normally be supported with parenteral nutrition (Ex. The patient receives chronic home PN); The patient is admitted to the ICU for treatment of thermal injury (burns); The patient is admitted to the ICU for palliative care; The patient is moribund and not expected to survive 24 hours; The patient is brain dead or suspected to be brain dead; The patient was admitted to the study ICU directly from another ICU; The treating physician believes there is an absolute contraindication to treatment received in either study arm.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Centralised, password protected web-server. As in any centralised method (see examples of centralised phone/fax rdx) individual patient treatment assignment will not be revealed until the potential participant is determined to be truly eligible for the trial and patient identifiers are submitted over the web. Persons recruiting patients into the trial will not be able to predict or influence treatment assignments.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computerised (SAS)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1015 0
Government body
Name [1] 1015 0
Address [1] 1015 0
16 Marcus Clarke Rd, Canberra, 2600 ACT, Aus
Country [1] 1015 0
Primary sponsor type
University of Sydney
Sydney, NSW 2006, Australia
Secondary sponsor category [1] 878 0
Name [1] 878 0
Address [1] 878 0
Country [1] 878 0

Ethics approval
Ethics application status
Ethics committee name [1] 287558 0
Northern Sydney Health Human Research Ethics Committee
Ethics committee address [1] 287558 0
Royal North Shore Hospital, Research Office, St. Leonards, NSW
Ethics committee country [1] 287558 0
Date submitted for ethics approval [1] 287558 0
Approval date [1] 287558 0
Ethics approval number [1] 287558 0

Brief summary
When a critically ill patient cannot tolerate feeding delivered into the stomach, a special feeding solution (parenteral nutrition) is commonly given directly into the blood stream (intra-venous) to feed the patient. A recently published review of the literature suggested that lives could be saved if intra-venous feeding was provided earlier (within 24 hours of intensive care unit (ICU) admission) than it is currently provided.

Because intra-venous feeding may be more expensive than standard care, we plan to conduct a multi-centre randomised controlled trial comparing the effects of early intra-venous feeding to standard care in patients who require at least two days of care in the intensive therapy unit. The trial will show whether earlier intra-venous feeding improves survival, reduces hospital length of stay and improves other measures of the patient's severity of illness.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35433 0
Address 35433 0
Country 35433 0
Phone 35433 0
Fax 35433 0
Email 35433 0
Contact person for public queries
Name 9931 0
Dr. Gordon S. Doig
Address 9931 0
Pacific Highway
St. Leonards,
NSW 2065
Country 9931 0
Phone 9931 0
02 9926 8656
Fax 9931 0
Email 9931 0
Contact person for scientific queries
Name 859 0
Dr. Gordon S. Doig
Address 859 0
Pacific Highway
St. Leonards,
NSW 2065
Country 859 0
Phone 859 0
02 9926 8656
Fax 859 0
Email 859 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary